Acid α-glucosidase (AAG)

Overview

Acid α-glucosidase (AAG), also known as acid maltase or α-1,4-glucosidase, is an enzyme that hydrolyzes α-glucosidic bonds at the non-reducing ends of oligosaccharides, disaccharides, and glycogen, releasing free glucose. Two distinct enzymes are commonly referred to under the α-glucosidase name: the lysosomal acid form, which degrades glycogen at acidic pH inside the lysosome, and the neutral-pH intestinal brush-border forms (maltase-glucoamylase and sucrase-isomaltase) that complete the terminal digestion of dietary starch after it has been broken down by salivary and pancreatic amylases such as AMY1C. Inherited deficiency of the lysosomal enzyme causes Pompe disease, a glycogen storage disorder treated by enzyme replacement therapy.

Pharmacologically, α-glucosidase is best known as a target for glycemic control. Because the intestinal enzyme governs the final step converting oligosaccharides to absorbable glucose, inhibiting it slows carbohydrate absorption and blunts postprandial glucose excursions — the mechanism of acarbose, the reference inhibitor used in type 2 diabetes mellitus and the standard positive control in inhibition assays. This makes the enzyme a common screening target in natural-product and food-science research, where plant phenolics and flavonoids (luteolin, rutin, chlorogenic acid, ferulic acid, gallic acid, caffeic acid, rosmarinic acid, resveratrol), soluble dietary fibers, and food-derived peptides are evaluated for inhibitory potency, typically alongside antioxidant assays measuring reactive oxygen species scavenging. Such studies often pair α-glucosidase inhibition with related endpoints relevant to metabolic and neurodegenerative disease, including insulin resistance, oxidative stress, and inhibition of acetylcholinesterase, butyrylcholinesterase, or tyrosinase, and commonly use molecular docking and molecular dynamics simulation to characterize how candidate inhibitors engage the enzyme's active site.

Recent Publications Summary

Recent research has extensively evaluated α-glucosidase inhibition as a therapeutic strategy for managing type 2 diabetes and glycemic control. Investigations spanning natural products, synthetic compounds, and delivery systems have identified numerous candidates that potently inhibit this carbohydrate-hydrolyzing enzyme, with many demonstrating superior efficacy to the reference drug acarbose.

Natural plant-derived compounds from diverse botanical sources have shown considerable α-glucosidase inhibitory potential. Extracts from Aleuritopteris bicolor 42531324Jul and Actinidia arguta pomace displayed remarkable inhibitory activity 42405437Jul, while luteolin extracted from Chrysanthemi Indici Flos via green chemistry methods demonstrated mixed-type inhibition and synergistic potentiation when combined with acarbose 42406988Jul. Chia seed extracts inhibited multiple carbohydrate-degrading enzymes including α-glucosidase 42313210Jun, and black highland barley anthocyanins exhibited reversible mixed-type inhibition with an IC50 of 8.31 μg/mL 42068808May. Usnea cornuta achieved particularly potent inhibition with an IC50 of 2.59 ± 2.23 μg/mL, with menegazziaic acid identified as a key bioactive constituent through molecular docking 42284305Jun. Hawthorn leaves 42141147May, sea buckthorn juice fermented with lactic acid bacteria 41935456Apr, sunflower meal extract containing chlorogenic acid 41844108Mar, and oolong-white mulberry leaf combinations 42090917May all demonstrated significant α-glucosidase inhibitory capacity. Garcinia nujiangensis biphenyl derivatives, particularly compound 10, achieved an IC50 of 37.80 ± 1.43 μg·mL⁻¹, approximately 7 times stronger than acarbose 42297079Jun.

Synthetic and semi-synthetic compounds have achieved exceptional inhibitory potencies. A food-derived peptide, YAPSW, exhibited an IC50 of 0.126 ± 0.008 mM, surpassing acarbose 42118964May. Thiazine-based hybrids displayed IC50 values of 3.10–3.60 μM, outperforming the reference drug 42119837May. N-propylcarbazole-1,3-thiazole derivatives, particularly compound 5k, achieved an IC50 of 6.25 ± 0.17 μM, substantially exceeding acarbose's potency 42033845Apr. Chromenone-linked spiro compounds reached approximately 16-fold greater potency than acarbose 42000452Apr, while thiazole-hydrazine hybrid TR6 demonstrated ~15-fold greater activity with a KI of 0.452 ± 0.093 μM 41855632Mar. Methyl-glycosyl furanose-based sulfonium derivatives showed selective maltase inhibition with compound LY-23 reaching an IC50 of 0.18 ± 0.03 μM 41849948Mar, and imidazo-thiadiazole pyrrole derivatives outperformed acarbose 41576694Jan. Structure-activity relationship analyses revealed that halogenation and hydroxyl substitution strengthened inhibitory potency through improved binding interactions within the enzyme active site.

Novel delivery systems enhanced bioactivity and efficacy. Mulberry-derived zwitterionic lipid nanoparticle encapsulating 1-deoxynojirimycin efficiently inhibited α-glucosidase while enabling controlled release in the gastrointestinal tract 42112609May. Ascorbic acid-functionalized zinc oxide nanoparticles demonstrated dose-dependent α-glucosidase inhibition with improved bioavailability 42047278Apr, while selenium-conjugated Rehmannia glutinosa polysaccharide nanoparticles exhibited substantially greater inhibitory activity than free polysaccharides 41794449Mar. Mechanistic studies consistently revealed reversible, mixed-type inhibition as the predominant mode, with molecular docking and dynamics simulations demonstrating binding within the enzyme's active site through hydrogen bonding and hydrophobic interactions. Phenolic and flavonoid compounds, including chlorogenic acid and cyanidin-3-O-glucoside, were commonly associated with inhibitory capacity, and synergistic combinations targeting both α-glucosidase and α-amylase showed enhanced glycemic suppression 42105553May.

What Changes, What Holds

1. α-Glucosidase inhibition remains a central drug-development strategy for glycemic control
REINFORCES Recent work mainly strengthens the existing view that this enzyme is a validated target for postprandial glucose lowering and that many new candidates can match or exceed acarbose in vitro 42531324Jul42405437Jul. What changes is not the role of the enzyme, but the density of supporting examples and the apparent breadth of chemical space now being mined. The baseline account already framed α-glucosidase as a standard screening target; these studies mostly sharpen that picture rather than alter it.

2. Natural products continue to expand the inhibitor pool without changing the core model
REINFORCES Plant extracts and phytochemicals add more potency examples to the established screening literature, but they do not revise the baseline understanding that α-glucosidase is a common natural-product target 42406988Jul42284305Jun. The mixed-type kinetics, docking support, and synergy with acarbose fit comfortably within the existing framework of phenolics and flavonoids as recurring inhibitor classes. The main implication is practical: the natural-product space remains productive, not conceptually new.

3. Synthetic optimization is pushing potency higher, but the target biology is unchanged
REINFORCES New scaffolds and peptide-like inhibitors reinforce the baseline message that α-glucosidase is highly druggable and that structure-activity tuning can improve binding 42118964May42033845Apr. Even the strongest compounds here are still being used in the same way: as inhibitors of the intestinal carbohydrate-digestion step that acarbose already targets. The important shift is quantitative, not conceptual, and the mixed results across chemotypes suggest potency gains may depend heavily on scaffold-specific chemistry rather than a single general rule.

4. Formulation advances broaden delivery options but do not alter α-glucosidase’s established role
REINFORCES Nanoparticle and conjugate systems extend the baseline pharmacology by improving how known inhibitors are delivered, yet they leave the underlying mechanism intact 42112609May42047278Apr. These studies support the idea that bioavailability and controlled release can matter as much as intrinsic enzyme affinity, but they do not challenge the established account of α-glucosidase as a glycemic-control target. The mechanistic emphasis on reversible mixed-type inhibition and docking simply restates the dominant pattern already described.

Overview update candidates: none.